Why Earn Your EngScD in Biomedical Engineering at Columbia?

Columbia gives you a rigorous Ivy League education in the heart of a vibrant global city for unmatched opportunities and impact.

As a student, you’ll benefit from:

• New York City
  Join top talent in one of the world’s most exciting and influential cities. Students choose Columbia Engineering over MIT, Berkeley, and others because of the New York City ecosystem of research and enterprise that can’t be found anywhere else. 
   
• Groundbreaking Faculty
  Work with researchers, teachers, and scholars who are pushing innovation forward. Over 45 strong, our faculty includes numerous award recipients, individuals with deep industry experience, and researchers working on cutting-edge projects like using machine learning to study the microenvironment of tumors or developing biomaterials that can reprogram the body’s immune system to fight cancer, infection, and autoimmune disease. 
   
• Broad Departmental Expertise
  You’ll find faculty engaged in exciting research in areas including genomics and computational modeling; neural engineering; biomaterials and tissue engineering; biomechanics; biosignals and biomedical imaging; and robotics and control of biological systems.
   
• Columbia University
  With a PhD from Columbia, you’ll join one of the world’s most international, accomplished networks of researchers and alumni. Your Ivy League credential will open doors wherever you go and the relationships you build here will accelerate your career. 

See Full Program Details

About the Study

Journal: Nature Cardiovascular Research

The study is titled “An engineered human cardiac tissue model reveals contributions of systemic lupus erythematosus autoantibodies to myocardial injury.”

Authors are: Sharon Fleischer1,*, Trevor R. Nash1,*, Manuel A. Tamargo1, Roberta I. Lock1, Gabriela Venturini2, Margaretha Morsink1, Pamela L. Graney1, Vanessa Li1, Morgan J. Lamberti1, , Martin Liberman1, Youngbin Kim1, Daniel N. Tavakol1, Richard Z. Zhuang1, Jaron Whitehead1, Richard A. Friedman3,4, Rajesh K. Soni5, Jonathan G. Seidman2, Christine E. Seidman2,6,7, Laura Geraldino-Pardilla8, Robert Winchester8,9 and Gordana Vunjak-Novakovic1,8,10,‡

1Department of Biomedical Engineering, Columbia University, New York, NY, USA

2Department of Genetics, Harvard Medical School, Boston, MA, USA

3Biomedical Informatics Shared Resource, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA

4Department of Biomedical Informatics, Columbia University, New York, NY, USA

5Proteomics and Macromolecular Crystallography Shared Resource, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA

6Division of Cardiovascular Medicine, Brigham and Women’s Hospital & Harvard Medical School, Boston, MA, USA

7Howard Hughes Medical Institute, Chevy Chase, MD, USA

8Department of Medicine, Columbia University, New York, NY, USA

9Columbia Center for Translational Immunology, Columbia University College of Physicians and Surgeons, New York, NY, USA

10College of Dental Medicine, Columbia University, New York, NY, USA

The study was supported by. National Institutes of Health (P41EB027062 and 3R01HL076485 to G.V-N.), the American Heart Association (19TPA34910217 to R.W.), a Pfizer Aspire research award (WI237809 2018 ASPIRE US Rheumatology to R.W.), and the National Science Foundation (NSF1647837 to G.V-N.).

The authors declare no financial or other conflicts of interest.